

**NATIONAL INSTITUTE FOR HEALTH AND CARE
EXCELLENCE**

HEALTH TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Scoping

**STA Midostaurin for treating advanced systemic
mastocytosis [ID1573]**

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?

A stakeholder stated there was inequality for people with rare diseases because there is less evidence, and inequality in treatments appraised via the single technology appraisal process compared with the highly specialised technologies process. Another stakeholder stated that people who live in regions less well served by knowledgeable consultants may be at a disadvantage if midostaurin is not recommended.

2. What is the preliminary view as to what extent these potential equality issues need addressing by the committee?

These issues do not relate to protected characteristics as defined by the Equality Act 2010. The committee will consider the best available evidence when making recommendations during the appraisal process.

3. Has any change to the draft scope been agreed to highlight potential equality issues?

No.

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the matrix been made?

No additional stakeholders were identified.

Approved by Associate Director (name): Jasdeep Hayre

Date: 11/12/2019